Description
AVZO-023 is an experimental oral medication currently being studied in clinical trials for advanced solid tumors, including breast cancer. It is being investigated to see if it can help stop cancer growth. It is a selective inhibitor of CDK4. The trials are in Phase 1, which means researchers are primarily looking at its safety and determining the right dose. It is being tested alone and in combination with other investigational drugs (like AVZO-021) and standard treatments (like endocrine therapy). While the main trials listed are for breast cancer, the drug is being studied in advanced solid tumors, which could potentially include colorectal cancer in the future, although specific CRC trials are not listed in our database currently. The trials are still recruiting participants.
Mechanism of Action
AVZO-023 works by selectively inhibiting CDK4 (Cyclin-Dependent Kinase 4). CDK4 is a protein involved in cell growth and division. By blocking CDK4, AVZO-023 aims to stop cancer cells from growing and multiplying. It is being studied both as a single agent and in combination with other drugs.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.